key: cord-1041885-m4q1fxxg
authors: Paoletti, Giovanni; Racca, Francesca; Piona, Alessandra; Melone, Giulio; Merigo, Morena; Puggioni, Francesca; Ferri, Sebastian; Azzolini, Elena; Lagioia, Michele; Lamacchia, Donatella; Cataldo, Giuseppe; Cecconi, Maurizio; Canonica, Giorgio Walter; Heffler, Enrico
title: Successful SARS-CoV-2 vaccine allergy risk-management: the experience of a large Italian University Hospital
date: 2021-04-08
journal: World Allergy Organ J
DOI: 10.1016/j.waojou.2021.100541
sha: 28564cb0aa1b7be11364708d8fe797f91f493f5c
doc_id: 1041885
cord_uid: m4q1fxxg

BACKGROUND Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines have been recently approved, and public concern regarding the risk of anaphylactic reactions arised after few cases during the first days of mass-vaccination. Polyethylene glycol (PEG) has been suggested as the most probable culprit agent for allergic reactions. OBJECTIVE We describe the allergy work-up protocol implemented for the vaccination campaign in our Center, aiming to allow the greatest number of people to be vaccinated safely. METHODS the protocol included the self-report of a history of suspected drug or vaccine allergies, and subsequent teleconsultation and allergometric tests for PEG and Polysorbate 80 (PS80). A desensitizing protocol of vaccine administration was applied to patients sensitized only to PS80, and to those with a suspect allergic reaction after the first vaccine dose. RESULTS 10.2% (414 out of 4042) of the entire vaccine population have been screened: only one patient resulted allergic to PEG and therefore excluded from the vaccination. Another patient was sensitized to PS80 only and safely vaccinated applying the desensitizing protocol. Seven subjects without a previous history of allergic disease experienced suspect hypersensitivity reactions to the first administered dose: one of them resulted allergic to PEG and was excluded from the second dose, while the others safely completed the vaccination with the desensitizing protocol. CONCLUSION a careful allergological risk-assessment protocol significantly reduces the number of patients who would have avoided SARS-CoV-2 vaccination for their allergies and to effectively identify and manage those rare patients with sensitization to PEGs and/or PS80.

J o u r n a l P r e -p r o o f Ethics statement: The protocol here described was agreed with the Medical and Health Department and the Clinical Quality Department of the two hospitals, and approved by the internal review board. All the subjects evaluated were informed of the protocol and gave their informed consent.

Editorial policy confirmation and agreement: all the Authors confirm that they consent the publication of this article, and agree with the Editorial policy.

Availability of data and materials: upon request.

J o u r n a l P r e -p r o o f ABSTRACT: 1 BACKGROUND: Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) 2 vaccines have been recently approved, and public concern regarding the risk of anaphylactic 3 reactions arised after few cases during the first days of mass-vaccination. Polyethylene glycol 4 (PEG) has been suggested as the most probable culprit agent for allergic reactions. The two main SARS-CoV-2 vaccines that have so far been approved are novel mRNA vaccines 61 encoding the "spike" protein of the virus inside a lipid nanoparticle. As most allergens tend to be 62 proteins, and due to the fact that these vaccines lack proteins in their excipients, the most probable 63 culprit of hypersensitivity reactions could be located inside the lipid particle, and in particular in its Table 1 ). Conversely, patients for whom the suspicion of 96 previous allergic reactions to the excipients or the suspicion of mastocytosis was not confirmed, 97 were asked to proceed with the vaccination. No patient with suspect systemic mastocytosis was screened.

The distribution of patients evaluated in the allergy work-up protocol is summarized in Figure 2 . 138 Seven people reported suspected hypersensitivity reactions to the first dose of vaccine (see Table 3 ); 139 none of these had a previous clinical history suggesting an increased allergological risk for 140 vaccination, and therefore were not previously screened in our risk-assessment protocol. Only one 141 of them (the only one with a clear immediate reaction) tested positive for both PEG and PS80 142 allergy tests and therefore was excluded from the second administration; all the others received 143 successfully the second dose of the vaccine with the desensitizing scheme (see Table 2 The main result of this study is that the application of an accurate protocol for the identification and The effectiveness of a mass vaccination campaign like the one currently underway for SARS-CoV-172 2 is closely related to the speed with which as many people as possible are vaccinated. A major 173 obstacle to this process is vaccine hesitation that may be at least in part due to previous reported 174 allergic reactions [30] . A careful protocol of identification and management of patients with 175 previous allergic reactions, in particular to drugs, is therefore essential to contribute to the success In conclusion, our study demonstrates that a careful allergological risk-assessment protocol is able 192 to significantly reduce the number of patients who would have avoided SARS-CoV-2 vaccination 193 and to effectively identify and manage those rare patients with sensitization to PEGs and / or PS80. 194 This also clearly highlights one of the fundamental roles that the allergist has during a pandemic 195 like the one we are experiencing, which is added to the careful management of allergic patients 

Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for 286

Polyethylene glycols (PEG) and related 293 structures: overlooked allergens in the perioperative setting. A A Case Rep